Servier

News

Amgen shares down as heart failure drug disappoints in phase...

Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug omecamtiv mecarbil disappointed in a large phase 3 trial.

News

Servier to acquire Danish cancer biotech Symphogen

France’s Servier has signed a deal to buy the Danish biotech Symphogen, which specialises in antibody-based therapies for cancer.

Sales & Marketing

Servier reveal how they are using data to empower their fiel...

The French independent pharmaceutical Servier is putting data at the foundation of its customer relationship management strategy.

News

France's Servier finally goes on trial over Mediator safety ...

More than a decade after a scandal over drug safety in France first broke, the pharma company Servier is to go on trial over its weight loss drug Mediator, which is thought to have caused b

News